SRAX Inc. (NASDAQ: SRAX) Partners with Consumer Packaged Goods (CPG) Brands, Unveils BIG Rewards

• SRAX has developed an exclusive consumer-managed data marketplace
• The company offers its proprietary BIGtoken platform
• SRAX has entered into new partnerships to launch BIGtoken’s BIG Rewards(TM)

SRAX Inc. (NASDAQ: SRAX) is a digital-marketing and data management technology company based in Los Angeles, California. The company provides marketers, content owners and consumers with tools to unlock the value of data. Its technology unlocks this data to reveal brands’ core consumers and their characteristics across marketing channels, enabling businesses to better reach their customer bases. Additionally, through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where consumers can own their own data and get paid for the release of that data. Via BIGtoken, consumers earn rewards when they opt into sharing their data and when that data is purchased.

Fundamentally, SRAX is focusing on privacy and data ownership – an invaluable approach in this age of Facebook, Twitter, Snapchat, LinkedIn and the like – along with concerns over the protection of personal data. The company’s vision is to build the most valuable opted-in consumer dataset worldwide. Today’s contemporary consumers expect to keep data private but also receive compensation for releasing data once they decide to do so. This critical need has created a demand for companies like SRAX, fluent in navigating the legal and ethical complications involved in data privacy. Ibotta, another company whose platform ‘doles out rewards’ to consumers in exchange for data and in-app purchases, recently secured funding at a $1 billion valuation (http://ibn.fm/TQM91).

With SRAX’s BIGtoken platform, consumers have control over what data is shared, who can purchase it and how it’s used. Consumers are rewarded when they initially share their data and then each time that data is accessed. In addition, they can engage with their community by making friends and joining teams (http://ibn.fm/7Pxht).

Once consumers grant consent to allow businesses access to their data, BIGtoken sells that access in the form of anonymized segments; the platform can also remove access at any time. Once consent is granted, a mutually beneficial relationship is formed between SRAX and its customers. BIGtoken offers high-quality data that enables advertisers, for a premium, to have access to consumer-verified information for their campaigns. Moreover, consumers who sell access to their digital data receive compensation in the form of points, which they can redeem for cash or gift cards.

SRAX is growing numerous recurring revenue streams through its different platforms. Along with its BIGtoken platform, the company also offers its SRAX Platform, SRAX Social, SRAX IR, SRAX Auto, SRAX Fan and SRAX Shopper. SRAX is building technology that is creating proprietary data, in turn fostering long-term, recurring revenue.

The company continues to expand on its existing platforms and initiate new partnerships. Currently, SRAX has partnered with major Consumer Packaged Goods (CPG) brands to launch a new BIGtoken feature called BIG Rewards (http://ibn.fm/6DPCA). BIG Rewards enables marketers to engage BIGtoken’s almost 16 million users to participate in brand research and exclusive offers. Via BIG Rewards, BIGtoken users in the United States can earn bonus points for participating in exclusive promotions with specific brands and retailers, as well as for taking part in brand research. BIG Rewards provides users with the opportunity to benefit from discounts on their everyday purchases and enables users to receive payment instantly on those earnings.

“This commercial expansion will be extremely valuable in the shopper marketing space especially as data regulation continues to grow,” George Stella, vice president of SRAX Shopper, the company’s shopper marketing vertical, stated in a news release. “Increased data regulation will make it challenging for media partners to activate against the current state of data. BIG Rewards allows brands to position themselves as advocates for their customers’ privacy. It also enables the brands to create future-proof insights while driving verified purchases of products at their retail locations.”

SRAX continues to focus on tools that deliver a digitally competitive advantage for brands in the CPG, automotive, investor relations luxury, and lifestyle verticals. Notably, the company plans to expand into the European Union and to offer its proprietary BIGtoken platform in multiple languages. With the optimization and monetization of data becoming a multibillion-dollar business, SRAX is positioned to capitalize on this significant opportunity.

For more information, visit the company’s website at www.SRAX.com

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at  http://ibn.fm/SRAX

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) Built Strategically from Day One

• The company delivers premium, certified organic cannabis to Canada and international markets
• TGOD intends to explore strategic international markets with exclusive licensing deals and partnerships
• The company has set its sights on the beverage industry as it continues to look forward

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF), a premium, global organic cannabis firm, is creating a sustainable and successful company through its careful planning and strategic growth strategy implementation. The company is focused on the medical cannabis markets in Canada, Europe, the Caribbean and Latin America, as well as the Canadian adult-use market.

TGOD’s strategic approach is unique, combining a focus on growing organic products and implementing logistical and infrastructure controls not often seen with industry competitors. This results in a premium crop. The company has also partnered with the world’s second-largest power management company, Eaton, and Canada’s second-largest construction management company, Ledcor, to ensure ultimate use of space and power. One of only three certified organically grown cannabis companies in Canada, TGOD is committed to maintaining a competitive edge at home and abroad.

TGOD’s vision is to become the global leader in delivering premium organic cannabis solutions that enhance its customers’ lives. The company’s product and process of growth are certified organic by the industry’s leading certification bodies, Ecocert and ProCert. TGOD is producing high-quality cannabis in living soil with established organic growing techniques and leading-edge intellectual property. Its living soil is free of pesticides, herbicides and synthetic nutrients, and products grown in this medium command a premium price.

TGOD’s focus on quality control and production efficiency have enabled it to enjoy healthy profit margins, and the company is acting on its mission to become a household name in the global cannabis community. To become a global leader, TGOD consistently explores strategic international opportunities. The company has already secured exclusive licensing deals in Canada and select international markets. Through a partnership with Epican, a vertically integrated Jamaican cannabis company in which TGOD has acquired a 49.18 percent interest, TGOD provides a platform to export its branded, premium Jamaican-grown cannabis products to select international jurisdictions for medical purposes. A joint venture with Denmark’s Queen Genetics/Knud Jepsen aims to develop and patent innovative and commercially valuable, elite cannabis genetics. The combined run rate of the Canadian-located Hamilton and Valleyfield facilities, along with the Jamaican domestic expansion and Denmark pilot, ramp up TGOD’s production to 219,000 kg, and the company hasn’t stopped there.

HemPoland, a fully owned subsidiary of TGOD, is providing a strategic cannabis gateway to the 750 million people in Europe, while a joint venture with LLACA provides access to 7,600 potential retail locations in Mexico and its 640 million residents.

Every element of The Green Organic Dutchman – from the ground up – has been planned carefully, deliberately and strategically. TGOD is ideally located in Ontario and Quebec to reduce shipping distance and provide higher customer satisfaction with lower operating expenses in Canada. The two provinces represent almost two-thirds of the Canadian population, allowing TGOD to simplify logistics. The provinces also border six U.S. states, allowing the company to capitalize on an estimated 57 million potential recreational cannabis tourists. TGOD provides coast-to-coast distribution in Canada through Velvet Management Inc., a well-known distribution company, established in 1968, that manages the largest wine sales force in the country.

By leveraging innovative tech and low-cost power solutions, the company is positioned to be one of the highest-quality and lowest-cost producers in Canada. This is in large part due to strategic partnerships with Eaton, Ledcor Group and Hamilton Utilities Corp. These partnerships allow TGOD to build the most advanced hybrid facilities in Canada capable of producing cannabis at some of the lowest costs today.

Grown organically and at low costs, the final product demands a premium price in the marketplace, increasing TGOD’s margins.

As the company continues to look to the future, it has set its sights on the beverage industry. A 40,000-square-foot Innovation Campus is in the planning stages and will focus on developing consumer-preferred products across a wide range of categories and occasions. The company wants to explore high-quality organic edibles and beverages, a plan that provides TGOD with a strategic path into the large-scale beverage, beverage alcohol and cannabis edibles markets.

For more information, visit the company’s website at www.TGOD.ca

NOTE TO INVESTORS: The latest news and updates relating to TGODF are available in the company’s newsroom at http://ibn.fm/TGODF

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Developing Novel Nicotine Ingestion Method as Smoking Alternative

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), an innovative biotechnology company, has set its sights on using its proprietary drug delivery technology to provide an alternative method of nicotine ingestion that is safer than smoking. An article further discussing the company reads, “The technology, known as DehydraTECH(TM), is a patented, cost-effective delivery mechanism that has been shown to improve the ingestibility of cannabinoids, vitamins, nonsteroid anti-inflammatory drugs (NSAIDs) and nicotine. Now, Lexaria has partnered with one of the world’s largest tobacco firms to develop new, reduced-risk, oral nicotine products using the technology (http://ibn.fm/pddAe). . . . The deal funds Lexaria’s R&D program — and consumer product development — in exchange for certain DehydraTECH license rights and a minority equity interest in Lexaria Nicotine, a wholly owned subsidiary of Lexaria Bioscience Corp. An initial tranche of $1 million has been provided, with additional phases providing up to $12 million total. Lexaria has granted a license for its technology to be used in nicotine-based, oral-format products on an exclusive basis in the United States and a nonexclusive basis elsewhere globally, for which it will receive royalties on every dollar of revenue generated utilizing its technology.”

To view the full article, visit http://ibn.fm/dvdIc

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in more than 40 countries around the world and has patents granted in the United States and in Australia for utilization of its DehydraTECH delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office

Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Receives USPTO Allowance of Key Patent Covering DN-TNFa Platform Technology for Treating Cancer

INmune Bio (NASDAQ: INMB), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced its receipt of United States Patent and Trademark Office (“USPTO”) formal notice of allowance to Patent Application Serial No. 15/776,061. The patent, titled “CANCER PREVENTION AND THERAPY BY INHIBITING SOLUBLE TUMOR NUCROSIS FACTOR,” covers INmune’s INB03 Program that utilizes dominant negative TNFα (“DN-TNFα”) technology for treating cancer. “This is an important patent for INmune Bio, Inc. and provides exclusivity for use of our DN-TNFα technology for the treatment of cancer,” INmune Bio Assoc. General Counsel Joshua Schoonover said in the news release. “With the approval from the USPTO, and the positive indication of allowable subject matter in the international preliminary report on patentability for the corresponding international PCT patent application, published as WO/2017/106278, we expect this patent family should develop into global intellectual property rights.”

To view the full press release, visit http://ibn.fm/r6n5k

About INmune Bio, Inc.

INmune Bio, Inc. is a clinical-stage immunology company developing therapies targeting the innate immune system to fight disease. INmune Bio is developing two product platforms, the DN-TNFα Platform and an Immune Priming Platform, as well as multiple products related to these platforms that reengineer the patient’s innate immune system’s response to disease. In addition to INB03, the DN-TNFα Platform includes XPRO1595, a DN-TNFα protein biologic that targets soluble TNFα (sTNFα) and may have many beneficial effects in patients with Alzheimer’s disease by decreasing neuroinflammation; and NeuLiv, also a DN-TNFα protein biologic that may enable targeting of the underlying cause of non-alcoholic steatohepatitis (NASH), to help stop the disease and allow the liver to heal. The Immune Priming Platform includes INKmune, which is a natural killer (NK) cell therapeutic that primes the patient’s NK cells to attack minimal residual disease, the remaining cancer cells that are difficult to detect, which often cause relapse. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and neurodegenerative diseases. For more information, visit the company’s website at www.INmuneBio.com.

NOTE TO INVESTORS: The latest news and updates relating to INMB are available in the company’s newsroom at http://ibn.fm/INMB

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) Accelerate Shipments to Meet Demand for Premium Organic Cannabis Following Ontario Launch

Cannabis-focused research and development company The Green Organic Dutchman Holdings (TSX: TGOD) (OTCQX: TGODF), a leading producer of premium certified organic cannabis, today announced that initial demand has exceeded expectations following its August launch in Ontario, which marked the company’s entrance into Canada’s recreational market. Per the update, TGOD’s Unite Organic, a high-THC signature strain, is performing well online and at dispensaries and triggering a second OCS order earlier than initially anticipated. “We are thrilled to witness such strong sales and positive feedback from retailers and consumers across Ontario, Canada’s most populous province at 14.32 million people.  We can see from the initial response that demand for high-quality flower is strong,” TGOD CEO Brian Athaide said in the news release. “Our team is working hard to ramp up production of our premium organic products as we get ready to expand distribution with additional strains and product forms as well as to other provinces in the months ahead.  With our Hamilton hybrid greenhouse completed, and a second one nearing completion in Valleyfield, we are on track to distribute nationally early next year.”

To view the full press release, visit http://ibn.fm/fPAGn

About the Green Organic Dutchman Holdings Ltd.

The Green Organic Dutchman Holdings is a publicly traded, premium global organic cannabis company with operations focused on medical cannabis markets in Canada, Europe, the Caribbean and Latin America, as well as the Canadian adult-use market. TGOD also has organic hemp CBD oil operations in Canada, and through its wholly-owned subsidiary HemPoland distributes premium hemp CBD oil in EU. The company grows high-quality, certified organic cannabis with sustainable, all-natural principles. TGOD’s products are laboratory tested to ensure patients have access to a standardized, safe and consistent product. TGOD has a planned global capacity of 219,000 kgs. and is building 1,643,600 square feet of cultivation and processing facilities across Ontario, Quebec, Jamaica and Denmark. For more information, visit the company’s website at www.TGOD.ca.

NOTE TO INVESTORS: The latest news and updates relating to TGODF are available in the company’s newsroom at http://ibn.fm/TGODF

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

BMO Completes Placement of The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) Block

• BMO’s block offering of TGOD’s shares was fully subscribed
• TGOD’s CEO commented on the mutual benefits presented by the Aurora transaction
• Investment interest in TGOD has been heightened following completion of the transaction

In the wake of The Bank of Montreal’s (BMO) completion of a block trade of Aurora Cannabis (TSX: ACB) (NYSE: ACB) held shares of The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF), leadership is reportedly pleased to see that 28.8 million overhanging shares remaining from that transaction have been successfully placed, predominately with institutional asset managers.

Through a transaction with BMO, a block trade of 4.8 million shares was completed on Friday, September 6, at $2.96, clearing the remaining shares. Approximately 55-65 percent of the total block of shares was placed in the hands of institutional asset managers, with the balance being taken by retail investors. This transaction was felt by both parties to be beneficial to their long-term strategic goals. Due to the repatriation of TGOD’s premium organic cannabis, which was previously designated for Aurora, the transaction brings significant revenue and gross margin gains for TGOD. ACB continues to show its support for TGOD by maintaining over 16.6 million purchase warrants (http://ibn.fm/D5LKg).

“Aurora has been an excellent partner during TGOD’s build out phase; their investment was instrumental in our success,” Brian Athaide, CEO of TGOD, stated in a news release (http://ibn.fm/ewIIy). “The relationship added tremendous value across multiple areas of collaboration, including the initial design and construction of our Canadian facilities. This is the right next step in the relationship as both companies mature and our respective strategies evolve, also providing TGOD with new institutional investors.”

This clearing of the stock overhang enables TGOD to increase its number of institutional holders, and industry analysts have described TGOD’s stock as “a screaming deal” for interested investors.

TGOD is a publicly traded, premium global organic cannabis company with operations focused on medical cannabis markets in Canada, Europe, the Caribbean and Latin America, as well as the Canadian adult-use market.

For more information, visit the company’s website at www.TGOD.ca

NOTE TO INVESTORS: The latest news and updates relating to TGODF are available in the company’s newsroom at http://ibn.fm/TGODF

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Genprex, Inc.’s (NASDAQ: GNPX) TUSC2 Found to Prevent Tumor Growth in Triple-Negative Breast Cancer by Independent Researchers

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced that non-affiliated, independent researchers have reported in a recent study that TUSC2, a tumor suppressor gene and the active agent in Genprex’s Oncoprex(TM) immunogene therapy, prevented tumor growth in triple-negative breast cancer (“TNBC”). Currently considered an incurable cancer, there are limited therapeutic options available for TNBC. “The results of the study evaluating TUSC2 for the treatment of triple-negative breast cancer are encouraging,” Genprex Chairman and CEO Rodney Varner said in the news release. “We believe that the data reported in this Nature article by independent researchers supports our belief that TUSC2 may be effective to treat a variety of cancers, including some of the most deadly types of cancer.”

To view the full press release, visit http://ibn.fm/0ZRIh

About Genprex, Inc.

Genprex, Inc. is a clinical stage gene therapy company developing potentially life-changing technologies for cancer patients, based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex(TM) immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. For more information, visit the company’s website at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html